Mathai Mammen, SVP, Research & Early Clin Development at THERAVANCE INC (THRX), sold 7,000 shares at $34.34 ($236K) on 2013-04-30, disclosed to the SEC on 2013-05-02.
Scheduled sale ($236k) by SVP, Research & Early Clin Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $33.72 | 6,800 | $229K | 97.1% |
| 2 | $34.34 | 200 | $7K | 2.9% |
| Total | $33.74 avg | 7,000 | $236K | 100% |
| Filing → |
| THRX | SELL | 2013-08-01 | $256K | — | Filing → |
| THRX | SELL | 2013-02-22 | $155K | — | Filing → |
| THRX | SELL | 2012-11-06 | $150K | — | Filing → |